Abstract
Raynaud's phenomenon is a common condition characterized by vasospasm of the digital arteries and resulting cyanosis and redness. It often does not require pharmacologic management, but in some cases symptoms are severe and pharmacologic management is necessary. Calcium channel blockers are often used first-line, but in some patients are ineffective. Patients with severe symptoms or intolerance to available therapies have prompted exploration of alternative therapies, including endothelin antagonists, phosphodiesterase-5 inhibitors, antioxidants, newer vasodilators, statins, and botulinum toxin. These newer therapies provide the focus for this review. © 2010 Levien, publisher and licensee Dove Medical Press Ltd.
Author supplied keywords
Cite
CITATION STYLE
Levien, T. L. (2010). Advances in the treatment of Raynaud’s phenomenon. Vascular Health and Risk Management. Dove Medical Press Ltd. https://doi.org/10.2147/vhrm.s4551
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.